Return to MD Anderson Cancer Center

Return to Department of Thoracic and Cardiovascular Surgery

What's New
Faculty & Staff
  Jack Roth , M.D.
    Curriculum Vitae
    Conferences
Education
Specific Diseases
Videos
Research
F.A.Q.
Glossary of Terms
Web Links
Thoracic Center
Contact Information

 

  

Invitations to National or International Conferences- Jack A. Roth, M.D.

  1. Roth, J.A. and Rutherford, R.B. Effects of external counter-pressure in the treatment of hemorrhagic shock. Symposium on Radioactive Tracer Studies of the Circulation. Johns Hopkins Medical Institutions, Baltimore, MD, June 1970.
  2. Roth, J.A., ter Haar, A.M., Krajewski, C.A., and Williams, G.M. Nucleic acid synthesis in allograft endothelium. Surgical Forum, Atlantic City, NJ, October 1971.
  3. Roth, J.A., Silverstein, M.J., and Morton, D.L. Do metastases metastasize James Ewing Society, Maui, HI, April 1974.
  4. Roth, J.A., Golub, S.H., Grimm, E., Eilber, F.R., and Morton, D.L. Effects of surgery on in vitro lymphocyte function. Surgical Forum, Miami, FL, October 1974.
  5. Roth, J.A., Eilber, F.R., and Morton, D.L. The Role of radioisotope scintiscanning in the initial evaluation of melanoma patients. American College of Surgeons Regional Meeting, Santa Barbara, CA, January 1975.
  6. Roth, J.A., Golub, S.H., Holmes, E.C., and Morton, D.L. Effect of BCG immunotherapy on lymphocyte function in melanoma patients. Society of University Surgeons, Tucson, AZ, February 1975.
  7. Roth, J.A. Isolation of soluble tumor-associated antigen from human melanoma. James Ewing Society, New Orleans, LA, March 1975.
  8. Roth, J.A., Holmes, E.C., Reisfeld, R., and Morton, D.L. Immune responses to human lung carcinoma-associated antigens. American Association of Thoracic Surgeons, New York, NY, April 1975.
  9. Roth, J.A., Holmes, E.C., Reisfeld, R.A., and Morton, D.L. Purification of human melanoma-associated antigen. American Association for Cancer Research, San Diego, CA, May 1975.
  10. Roth, J.A., Morton, D.L., and Holmes, E.C. Lymphocyte protein and nucleic acid synthesis in response to autologous and allogeneic tumor-associated antigens. American Association for Cancer Research, Toronto, Ontario, Canada, May 1976.
  11. Roth, J.A., Zuckerbraun, L., and Cohn, D. Lymphosarcoma presenting as a parotid mass. American College of Surgeons, Southern CA Chapter, Palm Springs, CA, January 1977.
  12. Roth, J.A. Effect of adriamycin and high-dose methotrexate chemotherapy on in vivo and in vitro cell-mediated immunity in cancer patients. Society of Surgical Oncology, Hilton Head, SC, May 1977.
  13. Roth, J., Chee, D.C., Morton, D.L., and Holmes, E.C. In vitro lymphocyte stimulation by melanoma-associated antigens derived from fresh tumors and tissue culture cell lines. American Association for Cancer Research, Denver, CO, May 1977.
  14. Roth, J.A., Cudingnan R, Scott CR: Use of activated clotting time to monitor heparin during cardiac surgery. American College of Surgeons, Southern CA Chapter, Santa Barbara, CA, January 1978.
  15. Roth, J.A., Cukingnan, R., Brown, B.G., Gocka, E., and Carey, J.S. Factors influencing patency of saphenous vein grafts. Society of Thoracic Surgeons, Phoenix, AZ, January 1979.
  16. Roth, J.A. In vitro tests of human tumor immunity. National Cancer Institute, Bethesda, MD, April 1979.
  17. Roth, J.A., Grimm, E.A., Gupta, R.K., and Morton, D.L. Characterization of an immunoregulatory factor in extracts of lung carcinoma. National Student Research Forum, Galveston, TX, April 1980.
  18. Roth, J.A., Grimm, E., Gupta, R.K., Morton, D.L., and Eilber, F.R. Purification of an immunoregulatory factor in extracts of lung carcinoma. American Association for Cancer Research, San Diego, CA, May 1980.
  19. Roth, J.A., Grimm, E.A., Gupta, R.K., and Morton, D.L. Characterization and purification of an immunosuppressive factor in extracts of lung carcinoma. 4th International Congress of Immunology, Paris, France, July 1980.
  20. Roth, J.A., Grimm, E.A., Gupta, R.K., Ames, R., and Trahan, E. Presence of immunoregulatory factors in extracts from several histologically distinct human malignancies. Federation Proceedings, April 1981.
  21. Roth, J.A., Grimm, E., Gupta, R.K., Sugarbaker, P.H., and Ames, R. Suppression of lymphocyte proliferative and cytotoxic responses by human tumor-associated immunoregulatory factors. 14th International Leukocyte Culture Conference, Heidelberg, Germany, June 1981.
  22. Roth, J.A. Humoral immune responses to human primary and metastatic sarcomas detected by an enzyme-linked immunoabsorbant solid-phase assay. Surgical Forum, American College of Surgeons, San Francisco, CA, October 1981.
  23. Roth, J.A., Grimm, E.A., and Ames, R.S. Suppression of adherent cell function by human tumor-derived immunoregulatory factors (IRF). 9th International Researcg Congress, Davos, Switzerland, February 1982.
  24. Roth, J.A., and Ames, R.S. Shared antigens on paired primary and metastatic human sarcomas detected by autologous humoral immune responses. American Association for Cancer Research, St. Louis, MO, 1982.
  25. Roth, J.A., and Osborne, B.A. Detection of an immunosuppressive immunoregulatory factor in the sera of sarcoma patients by enzyme-linked immuno-assay and correlation with clinical course surgical forum. American College of Surgeons, Chicago, IL, October 1982.
  26. Roth, J.A., Davidson, D.D., Ames, R.S., and Schneider, P.D. Tumor stasis factor (TSF): A possible mechanism for the regulation of tumor cell proliferation. Association for Academic Surgery, San Diego, CA, November 1982.
  27. Roth, J.A., Scuderi, P., and Baldwin, R.W. Common antigens expressed by human primary and metastatic osteogenic sarcomas detected by monoclonal antibodies. 5th International Congress of Immunology, Kyoto, Japan, August 1983.
  28. Roth, J.A. Adjuvant Chemotherapy and Radiation Therapy for Esophageal Carcinoma. Invited Symposia Speaker. , Postgraduate Course of Southern Thoracic Surgical Association, Marco Island, FL, November 1983.
  29. Roth, J.A. Multidisciplinary Approach to Esophageal Cancer. Invited Symposia Speaker, Post-Graduate Course of the 3rd Annual USUHS Cardiothoracic Surgery Symposium, Bethesda, MD, October 1984.
  30. Roth, J.A., Scuderi, P., Westin, E., and Gallo, R.C. A novel approach to production of anti-tumor monoclonal antibodies: Antibody to a cell surface glycoprotein associated with transformation by a human oncogene. Society of University Surgeons, Chicago, IL, February 1984.
  31. Roth, J.A. Cell surface glycoprotein associated with oncogene transformation. UCLA Symposium on Molecular and Cellular Biology. Regulation of the Immune System, Park City, UT, March 1984.
  32. Roth, J.A., Scuderi, P., Westin, E., Restrepo, C., and Gallo, R.C. Production of a monoclonal antibody recognizing a cell surface glycoprotein associated with transformation by a human oncogene. American Association for Cancer Research, Toronto, Ontario, Canada, May 1984.
  33. Roth, J.A., Putnam, J.B., Wesley, M.N., and Rosenberg, S.A. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Society of Surgical Oncology, New York, NY, May 1984.
  34. Roth, J.A., Ames, R.S., Restrepo, C., Aaronson, S., Srivastava, S., Scuderi, P., and Westin, E. Detection of new cell surface determinants on cells transformed by human oncogenes. UCLA Symposia on Molecular and Cellular Biology, Leukemia 1985, Keystone, CO, January 1985.
  35. Roth, J.A., Ames, R.S., Restrepo, C., Scuderi, P., Scannon, P.J., and Lee, H.M. Human tumor antigen expression is induced on murine 3T3 cells following transformation by human oncogenes. American Association of Immunologists Mini Symposium, Anaheim, CA, April 1985.
  36. Roth, J.A., Ames, R.S., Restrepo, C., Pass, H.I., Scannon, P.J., and Lee, H.M. Cells transformed by a human oncogene (c-Ha-ras) and human tumor cells express a common cell surface antigen. American Association for Cancer Research, Houston, TX, May 1985.
  37. Roth, J.A., Pass, H.I., Flanagan, M.M., Graeber, G.M., Rosenberg, J.C., and Wesley, R. Randomized trial of pre- and postoperative cisplatin, vindesine, and bleomycin (DVB) chemotherapy in epidermoid carcinoma of the esophagus. 14th International Congress of Chemotherapy, Kyoto, Japan, June 1985.
  38. Pass, H.I., Rosenberg, S.A., Baker, A.R., Miser, J., Wesley, M., and Roth, J.A. Chest wall resection for primary, locally recurrent, and metastatic sarcomas. Society of Surgical Oncology, Houston, TX, May 1985.
  39. Roth, J.A. Changing Concepts in cancer surgery: lung metastases, patient selection, operative approaches, and results. Invited Symposia Speaker, Postgraduate Course of the American College of Surgeons, Chicago, IL, October 1985.
  40. Roth, J.A., Pass, H.I., Wesley, M.N., White, D., Putnam, J.B., Seipp, C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft tissue sarcomas. Southern Thoracic Surgical Association, Boca Raton, FL, November 1985.
  41. Ames, R.S., and Roth, J.A. Monoclonal antibody 45-2D9 recognizes a cell surface epitope common to a c-Ha-ras transfected NIH 3T3 cell line and human tumors. American Association of Immunologists. Mini Symposium, St. Louis, MO, April 1986.
  42. Rizzoni, W., Pass, H.I., Wesley, M., Rosenberg, S.A., and Roth, J.A. Reoperative pulmonary metastasectomies in patients with adult soft tissue sarcomas. Society of Surgical Oncology, Washington, D.C., May 1986.
  43. Roth, J.A. Clinical trials of chemotherapy as an adjuvant to surgery. Invited Symposia Speaker, Current Approaches for the Diagnosis and Treatment of Gastrointestinal Cancer, 13th Annual Clinical Conference, Houston, TX, November 1986.
  44. Roth, J.A., Lanza, L.A., Ames, R.S., Fry, K., Becker, D., and Lee, H. Immunotoxin 5-2D9 can mediate successful therapy of pulmonary metastases in vivo with potentiation by systemic monensin. 2nd International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, March 1987.
  45. Roth, J.A. Prognostic Indicators for soft tissue sarcoma patients with pulmonary metastases. Invited Symposia Speaker, International Symposium on Sarcomas, Tarpon Springs, FL, October 1987.
  46. Pogrebniak, H.W., Stovroff, M., Roth, J.A., and Pass, H.I. Melanoma metastasectomy results of a 16 year experience. Southern Thoracic Surgical Association, Boca Raton, FL, November 1987.
  47. Ajani, J., McMurtrey, M., Rich, T., Roth, J.A., Blackburn, R., DeCaro, L., Faintuch, J., Levin, B., Ryan, B., and Mountain, C. Prolonged chemotherapy (CT) of locally advanced squamous carcinoma of the esophagus (SCCE). 2nd International Congress on Neo-Adjuvant Chemotherapy. Paris, France, February 1988.
  48. Roth, J.A. Multimodality Therapy of Esophageal Cancer. Invited Symposia Speaker, 3rd Annual Symposium, The Cardiovascular Patient: State of the Art and Current Antibiotic Management, Austin, TX, March 1988.
  49. Yang, S.C., Owen-Schaub, L., Grimm, E.A., and Roth, J.A. In vitro cytolysis of human primary lung tumors by cytotoxic lymphocytes: Synergistic effects with interleukin-2, tumor necrosis factor-a, and OKT3. American Association for Cancer Research, New Orleans, LA, May 1988.
  50. Ames, R.S., North, S.N., Nicolson, G.L., and Roth, J.A. Expression of differentiation antigen gp74 by oncogene transformed rat cells and relationship to spontaneous metastatic potential. American Association for Cancer Research, New Orleans, LA, May 1988.
  51. Schneider. P.M., Hung, M.C., Tainsky, M.A., Ames, R.S., and Roth, J.A. : Epidermal growth factor receptor and neu gene abnormalities in human non-small cell lung cancer. American Association for Cancer Research, New Orleans, LA, May 1988.
  52. Slater, J.D., Ellerbroek, N.A., Barkley, H.T., McMurtrey, M., Mountain, C., Oswald, M.J., Roth, J.A., and Peters, L.J. Radiation therapy following resection of non-small cell bronchogenic carcinoma. American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 1988.
  53. Roth, J.A. Molecular genetics and biologic modifiers of lung cancer. Invited Symposia Speaker, American College of Surgeons, Cancer Symposium, Chicago, IL, October 1988.
  54. Roth, J.A. Cancer-induced immunosuppression: implications for therapy. Invited Symposia Speaker, American College of Surgeons, Postgraduate Course, Chicago, IL, October 1988.
  55. Roth, J.A. New Developments in the treatment of lung cancer. Texas Academy of Family Practice Medical Surgical Conference, McAllen, TX, April 1989.
  56. Roth, J.A. Multidisciplinary therapy of esophageal cancer. Invited Symposia Speaker, 24th. Annual Cancer Symposium of the Academy of Medicine of Cincinnati, OH, April 1989.
  57. Ajani, J., McMurtrey, M., Ryan, B., DeCaro, L., Rich, T., Abbruzzese, J., Jackson, D., Rodriguez, A., Faintuch, J., Levin, B., Mountain, C., Roth, J. Pre- and postoperative chemotherapy for operable adenocarcinoma of the esophagus (ACE). American Society of Clinical Oncology, San Francisco, CA, May 1989.
  58. Yang, S., Licciardello, J., Owen-Schaub, L., Grimm, E., Hong, W., Roth, J. Evaluation of combination low-dose tumor necrosis factor-a (TNF) and interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology, San Francisco, CA, May 1989.
  59. Fang, K., Li, Y.L., and Roth, J.A. Purification and characterization of a human tumor stasis factor. American Society of Clinical Oncology, San Francisco, CA, May 1989.
  60. Schneider, P.M., Hung, M.C., Chiocca, S.M., and Roth, J.A. : Alterations in epidermal growth factor receptor (EGFR) and neu gene expression in human non-small cell lung cancer (NSCLC). American Society of Clinical Oncology, San Francisco, CA, May 1989.
  61. Yang, S.C., Grimm, E.A., and Roth, J.A. Successful combination immunotherapy of murine pulmonary metastases using anti-CD3, interleukin-2 and tumor necrosis factor-?. Society of Surgical Oncology, San Francisco, CA, May 1989.
  62. Roth, J.A., Ajani, J., McMurtrey, M., Ryan, M.B., Natarajan, G., Mendiguren-Rodriguez, A., Faintuch, J., and Levin, B. Pilot study of pre- and postoperative combination chemotherapy for resectable adenocarcinoma of the esophagus. 4th World Congress of the International Society for Diseases of the Esophagus. Chicago, IL, September 1989.
  63. Fang, K.L. and Roth, J.A. Isolation and characterization of tumor stasis factor. American Association for Cancer Research, San Francisco, CA, May 1989.
  64. Yang, S., Rodriguez, A.M., Owen-Schaub, L., Grimm, E., Hong, W., and Roth, J.A. Combination low dose tumor necrosis factor-? (TNF) and interleukin-2 (IL-2) for non-small cell lung cancer: Clinical and in vitro effects. American College of Chest Physicians, Boston, MA, October 1989.
  65. Roth, J.A. Prognostic Indicators for Soft Tissue Sarcoma in Patients with Pulmonary Metastases. Invited Symposia Speaker, 75th Annual Clinical Congress, American College of Surgeons, Atlanta, GA, October 1989.
  66. Putnam, J.B. Jr, Lammermeier, D.E., McMurtrey, M.J., and Roth, J.A. Predicted postoperative pulmonary function correlates with operative mortality and long term survival following pneumonectomy in patients with primary lung carcinoma. Southern Thoracic Surgical Association, Scottsdale, AZ, November 1989.
  67. Yang, S.C., Grimm, E.A., and Roth, J.A. Alternative pathways for generating cytotoxic lymphocytes in vivo using anti-CD-3, interleukin-2 (IL-2) and tumor necrosis factor-?. Molecular Pathways of Cytokine Action, UCLA Colloquium, Park City, UT, January 1990.
  68. Yang, S.C., Grimm, E.A., and Roth, J.A. Immunodulatory effects of combination immunotherapy with low-dose interleukin-2 (IL-2) and tumor necrosis factor-? (TNF) in patients with non-small cell lung cancer (NSCLC). Cellular Immunity and the Immune Therapy of Cancer, UCLA Symposia, Park City, UT, January 1990.
  69. Ajani, J., Roth, J., Ryan, B., Putnam, W., Pazdur, R., Faintuch, J., Jackson, D., Rodriguez, A., Levin, B., DeCaro, L., McMurtrey, M., and Gutterman, J. Feasibility and toxicities of GM-CSF given with high-dose chemotherapy for resectable adenocarcinoma of the esophagus. American Society of Clinical Oncology, Washington, D.C., May 1990.
  70. Holoye, P., Ellerbroek, N., Komaki, R., Roth, J., McMurtrey, M., Ryan, B., DeCaro, L., Glisson, B., Pang, A., and Hong, W. Sequential chemotherapy (ICT), surgery (S), alternating CT and twice daily radiotherapy (XRT) in limited disease (LD), small cell lung cancer (SCLC). American Society of Clinical Oncology, Washington, D.C., May 1990.
  71. Dhingra, H., DeCaro, L., Roth, J., and Hong, W. Possible down staging of stage III(A) non-small cell lung cancer (NSCLC) in a randomized trial of surgery neoadjuvant chemotherapy (NA CHEMO) with cyclophosphamide (C), etopside (E), and cisplatin (P). American Society of Clinical Oncology, Washington, D.C., May 1990.
  72. Yang, S., Grimm, E., Hong, W., Parkinson, D., and Roth, J. Immunologic effects of combined immunotherapy with OKT3, interleukin-2 (IL-2) and tumor necrosis factor-? (TNF) in patients with non-small cell lung cancer (NSCLC). American Society of Clinical Oncology, Washington, D.C., May 1990.
  73. Fang, K., Jansen, J.G., and Roth, J.A. Purification and characterization of tumor stasis factor. American Association for Cancer Research, Washington, D.C., May 1990.
  74. Yang, S., Grimm, E.A., Roth, J.A. Anti-CD3 activation prior to interleukin-2 (IL-2) and tumor necrosis factor-? (TNF) enhances immunodulatory activity in vivo. American Association for Cancer Research, Washington, D.C., May 1990.
  75. Lazenby, A.W., Roth, J.A., Yang, S.C., Grimm, E.A. Interleukin-1 (IL-1) nonapeptide (?163-171), VQGEESNDK, synergizes with interleukin-2 (IL-2) in the generation of lymphokine activated killer cell activity (LAK). American Association for Cancer Research, Washington, D.C., May 1990.
  76. Mukhopadhyay, T., Cavender, A., Tainsky, M., Roth, J.A. Expression of antisense K-ras message in a human lung cancer cell line with a spontaneous activated K-ras oncogene alters the transformed phenotype. American Association for Cancer Research, Washington, D.C., May 1990.
  77. Schneider PM, Praeuer HW, Fink U, Hung M-C, Siewert JR, Roth, J.A. Comparison of neu (c-erbB2) gene expression in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and normal lung. American Association for Cancer Research, Washington, D.C., May 1990.
  78. Pass, H.I., Evans, S., Matthews, W.A., Perry, R., Roth, J.A., and Smith, P. In vitro, in vivo phototherapy of transfected human lung cancer. American Association for Thoracic Surgery, Toronto, Ontario, Canada, May 1990.
  79. Yang, S.C., Owen-Schaub, L., Mendiguren-Rodriguez, A., Grimm, E.A., Hong, W.K., and Roth, J.A. Combination immunotherapy for non-small cell lung cancer: Results using interleukin-2 and tumor necrosis factor-?. American Association for Thoracic Surgery, Toronto, Ontario Canada, May 1990.
  80. Roth, J.A. Surgery for Cancer of the Esophagus, Invited Symposia Speaker, Educational Symposium, American Society of Clinical Oncology, Washington, D.C., May 1990.
  81. Putnam, E.A. and Roth, J.A. Analysis of the effects of suramin on non-small cell lung carcinoma cell lines. First Annual Meeting on the Molecular Basis of Human Cancer, Frederick, MD, June 1990.
  82. Mukhopadhyay, T., Cavender, A., Tainsky, M., Roth, J.A. Antisense K-ras RNA causes partial reversion of transformed phenotype in a human lung cancer cell line containing a spontaneous K-ras mutation. 6th Annual Meeting on Oncogenes, Frederick, MD, June 1990.
  83. Schneider, P.M., Praeuer, H.W., Fink, U., Hung, M.-C., Siewert, J.R., Roth, J.A. Variation of neu (cerbB2) gene expression in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC). 15th International Cancer Congress, Hamburg, Germany, August 1990.
  84. Roth, J.A. and Ajani, J. Multidisciplinary therapy for esophageal cancer Invited Symposia Speaker. 15th International Cancer Congress, Hamburg, Germany, August 1990.
  85. Yang, S.C., Grimm, E.A., and Roth, J.A. Effects of low dose OKT3 induction on the anti-tumor immune response in cancer patients receiving interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF). American College of Surgeons, San Francisco, CA, October 1990.
  86. Roth, J.A. New insights into selecting patients likely to benefit from resection of pulmonary metastases. Invited Symposia Speaker, American College of Surgeons, San Francisco, CA, October 1990.
  87. Morice, R.C., Peters, E.J., Ryan, M.B., Putnam, J.B., Ali, M.K., and Roth, J.A. Exercise testing in the evaluation of patients at high risk for lung resection. American College of Chest Physicians 57th Annual Scientific Assembly, Toronto, Canada, October 1990.
  88. Gorenstein, L.A., Putnam, J.B., Balch, C.M., and Roth, J.A. Improved survival following resection of pulmonary metastases from malignant melanoma. Southern Thoracic Surgical Association Meeting, San Juan, PR, November 1990.
  89. Pogrebniak, H.W., Roth, J.A., Steinberg, S.M., Rosenberg, S.A., Pass, H.I. Re-operative pulmonary resection in patients with metastatic soft tissue sarcoma. Southern Thoracic Surgical Association Meeting, San Juan, PR, November 1990.
  90. Roth, J.A. Neoadjuvant therapy for non-small cell lung cancer. Invited Symposia Speaker, The M. D. Anderson Experience, The Department of Continuing Education in Health Sciences, UCLA Extension and the UCLA School of Medicine, Los Angeles, CA, December 1990.
  91. Roth, J. A. Molecular biology of non-small cell lung cancer. Invited Symposia Speaker. The Department of Continuing Education in Health Sciences, UCLA Extension, and the UCLA School of Medicine, Los Angeles, CA, December 1990.
  92. Roth, J.A. Surgical aspects of esophageal carcinoma. Invited Symposia Speaker. Second Alabama Cancer Congress, Birmingham, AL, March 1991.
  93. Roth, J.A. Approaches in treating early lung cancer. Investigational strategies for detection and intervention in early lung cancer. National Cancer Institute, Bethesda, MD, April 1991.
  94. Roth, J.A. Molecular and cellular biology of lung cancer. Invited Symposia Speaker, The 9th International Congress of Radiology Research, sponsored by University of California, Department of Radiation Oncology, Toronto, Ontario, Canada, July 9, 1991.
  95. Roth, JA Modulation of oncogene expression as a potential therapy for cancer, biomolecular recognition and targeting strategies in the prevention and treatment of disease. Invited Symposia Speaker, University of Virginia, Charlotte, VA, October 25, 1991.
  96. Lanza, L.A., Natarajan, G., Roth, J.A., and Putnam, J.B. Jr. Long-term survival following resection of pulmonary metastases from cancer of the breast. Southern Thoracic Surgical Association, 38th Annual Meeting, Orlando, FL, November 1991.
  97. Roth, J.A. Molecular approach for the prevention and treatment of lung cancer. Invited Symposia Speaker, 57th Annual Scientific Assembly, American College of Chest Physicians, San Francisco, CA, November 1991.
  98. Roth, J.A. Future directions in the treatment of esophageal carcinoma. Invited Symposia Speaker, International Conference on the Biology and Treatment of the Gastrointestinal Cancer, Frankfurt, Germany, February 1992.
  99. Roth, J.A.: Application of molecular biology to the diagnosis, prognosis, and therapy of thoracic cancers. Invited Symposia Speaker, First Annual General Thoracic Biology Club, Los Angeles, CA, April 1992.Roth, J.A. Molecular strategies for therapy and prevention of cancer. Invited Symposia Speaker, American Society for Clinical Oncology Educational Conference Early Detection of Cancer: Challenges for Molecular Biology, Washington, D.C., October 1992.
  100. Roth, J.A. Molecular biology of NSCLC. Invited Symposia Speaker, UCLA Educational Symposium, Los Angeles, CA, December 1992.
  101. Roth, J.A. Future directions in the biology and treatment of esophageal cancer. International Conference on Biology and Treatment of Gastrointestinal Malignancies, , 1992
  102. Roth, J.A. Pulmonary resection of metastatic hypernephroma. Invited Principal Discussant, Society of Thoracic Surgeons, San Antonio, TX, January 1993.
  103. Roth, J.A. Surgical approach to esophageal cancer. Invited Plenary Symposia Speaker. Southwest Oncology Group/Japanese Clinical Trials Summit, Honolulu, HI, February 1993.
  104. Roth, J.A. Gene therapy for lung cancer. Invited Symposia Speaker, Cancer Progress Conference, sponsored by Communitech Market Intelligence, Inc., New York, NY, February 1993.
  105. Roth, J.A. Modulation of oncogene and tumor suppressor gene expression for prevention and therapy of lung cancer. Invited Symposia Speaker, 4th IASLC Lung Tumor Biology Workshop, Airlie, VA, April 1993.
  106. Roth, J.A. Use of retroviral vectors for the delivery of antisense constructs. Invited Symposia Speaker, 84th Annual Meeting American Association for Cancer Research, Orlando, FL, May 1993.
  107. Roth, J.A. New insights into selecting patients likely to benefit from resection of pulmonary metastases. Invited Symposia Speaker, IASLC, Genoa, Italy, May 1993.
  108. Roth, J.A. Molecular genetic strategies for the prevention and therapy of lung cancer. Invited Symposia Speaker, IASLC, Genoa, Italy, May 1993.
  109. Roth, J.A. What's new in surgery Invited Symposia Speaker, IASLC Workshop - Controversies in staging and treatment of locally advanced non-small cell lung cancers, Brussels, Belgium, August 1993.
  110. Roth, J.A. Is an initial multifocal or diffuse appearance characteristic of adenocarcinoma in CLE Invited Symposia Speaker, 4th International Polydisciplinary Congress (O.E.S.O.), September 1993.
  111. Roth, J.A. Molecular biological approaches to cancer prevention and treatment. Invited W.G. Cosbie Lecture Symposia Speaker, The Royal College of Physicians and Surgeons of Canada, Vancouver, BC, Canada, September 1993.
  112. Roth, J.A. Surgical and neoadjuvant approaches to locally advanced, potentially resectable non-small cell lung cancer. Recent Advances in the Management of Lung Cancer, The UT Southwestern Medical Center, Dallas, TX, September 1993.
  113. Roth, J.A. Surgery for abdominothoracic metastatic disease. Invited Symposia Speaker, General Panel Discussion at the American College of Surgeons, San Francisco, CA, October 1993.
  114. Roth, J.A. Modulation of oncogene and tumor suppressor gene expression. Second International Conference on Gene Therapy of Cancer, San Diego, CA, November 1993.
  115. Roth, J.A. Targeting cancer genes. First International Conference on Gene Therapy & Vaccines for Cancer, Washington, D.C., January 1994.
  116. Roth, J.A. Modulation of oncogene of the tumor suppressor gene expression: an approach to the gene therapy of cancer. Invited Speaker, American Cancer Society, Orlando, FL, March 1994.
  117. Roth, J.A. Resection of N2/N3 lung cancer. Invited Professor, Society Surgical Oncology Meet the Professor, Houston, TX, March 1994.
  118. Roth, J.A. Gene Replacement strategies for therapy and prevention of lung cancer. Invited Symposia Speaker, American Association Cancer Research, San Francisco, CA, April 1994.
  119. Roth, J.A. The biology of lung cancer. Invited Symposia Speaker, 7th World Conference on Lung Cancer, Current Perspectives in the Treatment of Non-small Cell Lung Cancer Symposia, sponsored by Bristol-Myers Squibb Company, Colorado Springs, CO, June 1994.
  120. Roth, J.A. The Molecular biology of non-small cell lung cancer. 7th World Conference on Lung Cancer, Current Perspectives in the Treatment of Non-small Cell Lung Cancer Symposium, Colorado Springs, CO, June 1994.
  121. Roth, J.A. Gene replacement strategies for therapy and prevention of lung cancer. Ninth Aspen Cancer Conference Workshop: Mechanisms of Toxicity and Carcinogenesis, Aspen, CO, July 1994.
  122. Roth, J.A. Adenovirus-mediated gene therapy for malignant mesothelioma: a comparison of immunodeficient and immunocompetent tumor models. Invited Discussant, American Surgical Association 115th Annual Meeting, Chicago, IL., April 1994.
  123. Roth, J.A. Mutation in the p53 tumor suppressor gene in Barrett's esophagus is a marker for development of adenocarcinoma: results of an international multi-institutional prospective study. 75th Annual Meeting of the American Association for Thoracic Surgery, Boston, MA, April 1995.
  124. Roth, J.A. Molecular genetic differentiation between primary lung cancer and lung metastases of other tumors. Invited Discussant, 75th Annual Meeting of the American Association for Thoracic Surgery, Boston, MA, April 1995.
  125. Roth, J.A. Molecular genetics and lung cancer. Invited Keynote Speaker, Lung Cancer: Strategies for the 21st Century, Biology, Prevention and Management, University of Toronto, Toronto, Ontario, Canada, September 1995.
  126. Roth, J.A. Biology and management of stage I lung cancer. Invited Symposia Speaker, Lung Cancer: Strategies for the 21st Century, Biology, Prevention and Management, University of Toronto, Toronto, Ontario, Canada, September 1995.
  127. Roth, J.A. Gene replacement strategies for prevention and treatment of aerodigestive tract cancers. Invited Symposia Speaker, American Society for Therapeutic Radiology and Oncology 37th Annual Meeting, Miami Beach, FL October 1995.
  128. Roth, J.A. Clinical trials of p53 gene replacement. Invited Presentor, RPR Gencell Network Meeting, San Juan, PR, November 1995.
  129. Roth, J.A. Gene replacement for cancer. Invited Symposia Speaker, Novel Strategies Against Resistant Cancers: A Special Conference of the American Association for Cancer Research, Fort Myers, FL, November 1995.
  130. Roth, J.A. Gene replacement for cancer. Invited Symposia Speaker, Fourth International Conference on Gene Therapy of Cancer, San Diego, CA, November 1995.
  131. Roth, J.A. Gene replacement for cancer. Invited Symposia Speaker, New Cancer Strategies: p53 Diagnostics & Therapy, McLean, VA, March 1996.
  132. Roth, J.A. Gene replacement for cancer. Invited Speaker, Eleventh Aspen Cancer Conference Workshop: Mechanisms of Toxicity and Carcinogenesis, Aspen, CO, July 1996.
  133. Roth, J.A. Gene replacement for cancer. 5th IASCL Lung Tumor Biology Workshop, Ermatingen, Switzerland, August 1996.
  134. Roth, J.A. Gene therapy and the new biology. Invited Symposia Speaker, Lung Cancer-From Primary Care to Future Care, Duke University, Durham, NC, September 1996.
  135. Roth, J.A. Gene therapy for non-small cell lung cancer. Perspectives in Lung Cancer, Atlanta, GA, September 1996.
  136. Roth, J.A. Tumor suppressor gene replacement. American College of Surgeons, San Francisco, CA, October 1996.
  137. Roth, J.A. Stage changes after induction therapy. International Workshop on Intrathoracic Staging, IASLC, London, England, October 1996.
  138. Roth, J.A. Gene replacement for cancer. Gene Therapy-Current Clinical Status, London, England, October 1996.
  139. Roth, J.A. Regulatory issues in gene therapy. Invited Speaker Human Protection Workshop, Houston, TX, November 1996.
  140. Roth, J.A. Viral-mediated p53 gene replacement: preclinical models and clinical trials. Invited Speaker, 5th International Conference on Gene Therapy of Cancer, San Diego, CA, November 1996.
  141. Roth, J.A. Restoration of gene function for cancer. Invited Speaker, Congressional Caucus, STS/AATS Committee, Washington, DC, April 1997.
  142. Roth, J.A. Restoration of p53 function using gene therapy. Invited Speaker, Cambridge Healthtech Institute's Second Annual New Cancer Strategies: p53, Washington, DC, April 1997.
  143. Roth, J.A. Approaches to using genes as cancer therapies. Invited Speaker, American Association for Cancer Research, Sunrise Session, San Diego, CA, April 1997.
  144. Roth, J.A. Tumor suppressor genes. Invited Speaker, American Radium Society Annual Meeting, New York, NY, May 1997.
  145. Roth, J.A. Gene replacement strategies for cancer. Invited Speaker, 5th Annual Radiation Workshop at Round Top Gene Therapy Program, Houston, TX, May 1997.
  146. Roth, J.A. Gene therapy for lung cancer. Invited Speaker, Harvard Medical School General Thoracic Surgery, Cambridge MA, May 1997.
  147. Roth, J.A. Gene replacement strategies for cancer. Invited Symposium Speaker, Second Annual UCLA Human Gene Medicine Symposium, Los Angeles, CA, June 1997.
  148. Roth, J.A. Gene therapy innovations. Invited Speaker, RPR Gencell Development/Marketing Meeting, Boca Raton, FL, 1997.
  149. Roth, J.A. New approaches in drug development. Invited Discussant, American Society of Clinical Oncology, Los Angeles, CA, May 1998.
  150. Roth, J.A. Gene therapy in radiation oncology. Invited Speaker, 2nd Symposium on Concomitant Chemoradiotherapy, Vanderbilt University, Nashville, TN, August 1998.
  151. Roth, J.A. Combined modality approaches for surgically resectable non-small cell lung cancer. Invited Speaker, Lung Cancer 98: A Multidisciplinary Approach, Memorial Hospital Jacksonville, FL, October 1998.
  152. Roth, J.A. Genetics of lung cancer. Invited Speaker, Lung Cancer: A Revolution in Care, 1998-99 Workshop Tour, Alliance for Lung Cancer Advocacy, Support, and Education, Houston, TX, November 1998.
  153. Roth, J.A. Local and systemic gene replacement for cancer: treating metastases at the source. Invited Speaker, 29th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, November 1998.
  154. Roth, J.A. Gene replacement for cancer: local, systemic, and combined modality strategies. Invited Speaker, 7th International Conference on Gene Therapy of Cancer, San Diego, CA, November 1998.
  155. Roth, J.A. Gene replacement for cancer: local, systemic and adjuvant strategies. Invited speaker, The Ray A. Barlow Scientific Symposium on Gene Therapy in Cancer, Louisiana State University Medical Center, Shreveport, LA, January, 1999.
  156. Roth, J.A. Tumor suppressor gene therapy of cancer. Invited speaker, Society of Surgical Oncology, 52nd Annual Cancer Symposium, Orlando, Florida, March, 1999
  157. Roth, J.A. Gene replacement for cancer therapy. . Invited speaker., American Association for Thoracic Surgery, Nrew Orleans, LA, April, 1999
  158. Roth, J.A. Molecular basis for therapy in non-small lung cancer, Invited speaker, Canadian Association of Medical Oncologists, Toronto, Canada, April, 1999.
  159. Roth, J.A., p53 As a therapeutic gene for cancer, Invited speaker, American Society of Gene Therapy Scientifc Committee Program, Washington, D.C., June, 1999.
  160. Roth, J.A., Activation of apoptosis pathways in lung cancer, Invited speaker International Cancer Gene Therapy, London, England, July, 1999.
  161. Roth, J.A., Gene replacement for cancer: local, systemic, and adjuvant strategies, Invited speaker, The George Washington University Grand Rounds, Washington, D.C., July, 1999.
  162. Roth, J.A., Activation of apoptosis pathways in lung cancer, Lung Cancer Biology Workshop, Aspen, Colorado, August, 1999.
  163. Roth, J.A., Neo-adjuvant therapy, ASTRO School of Radiation Oncology , Washington, D.C., September, 1999.
  164. Roth, J.A., Viral and non-viral vectors for tumor suppressor gene replacement, AACR-NCI-EORTC, Washington, D.C., November, 1999.
  165. Roth, J.A., Restoration of tumor suppressor gene function: p53 and beyond 2000 Keystone Symposia, Keystone, CO, January, 2000.
  166. Roth, J.A., Gene replacement for cancer, Texas A & M University, 2000 Graduate Research Symposium, College Station, TX, March, 2000.
  167. Roth, J.A., Critical Issues of Cell-Based Vaccines and their Clinical Translation, 2nd Annual Walker's Cay Colloquium, Walker's Cay Island, Bahamas, March 8, 2000.
  168. Roth, J.A., Molecular Approach to Therapy and Prevention, International Conference on Basic and Clinical Aspects of Cell Cycle Control, Siena, Italy, May 2000.
  169. Roth, J.A., Gene Replacement for Cancer, The Nobel Conference, 2000, Stockholm, Sweden, August 22, 2000.
  170. Roth, J.A., Local and Systemic Pro-Apoptotic Gene Replacement for Non-Small Cell Lung Cancer, IASLC 9th World Conference on Lung Cancer, Tokyo, Japan, September 13, 2000.
  171. Roth, J.A., Biology of Lung Cancer, Lung Cancer Investigators Meeting, Hakone, Japan, September 17, 2000.

    172. Back to Top